PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27040396-8	2016	Interestingly, the latter response was driven by CXCL8 autocrine signaling because it was abolished by SB225002, an antagonist that prevents CXCL8 from binding to CXCR2.	SB 225002	103-111	C-X-C motif chemokine ligand 8	Homo sapiens	49-54	
31769424-7	2019	Mechanistically, IL-8-induced myotube atrophy is inhibited by treatment with the CXCR2 antagonist, SB225002, or by treatment with the ERK1/2 inhibitor, U0126.	SB 225002	99-107	C-X-C motif chemokine ligand 8	Homo sapiens	17-21	
30592634-5	2019	To elucidate the function of paracrine CXCL8 in AML, we blocked CXCL8 binding to the C-X-C motif chemokine receptor (CXCR)2 in the AML cells using SB225002.	SB 225002	147-155	C-X-C motif chemokine ligand 8	Homo sapiens	64-69	
27040396-8	2016	Interestingly, the latter response was driven by CXCL8 autocrine signaling because it was abolished by SB225002, an antagonist that prevents CXCL8 from binding to CXCR2.	SB 225002	103-111	C-X-C motif chemokine ligand 8	Homo sapiens	141-146	
26297794-8	2015	Furthermore, the selective CXC chemokine receptor 2 and formyl peptide receptor 2 antagonists, SB225002 and WRW4, respectively, blocked the synergy between IL-8/CXC chemokine ligand 8 and serum amyloid A1alpha in neutrophil chemotaxis in vitro, indicating that for synergy their corresponding G protein-coupled receptors are required.	SB 225002	95-103	C-X-C motif chemokine ligand 8	Homo sapiens	156-160	
23611835-1	2013	SB225002 (SB) is an IL-8 receptor B (IL-8RB) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.	SB 225002	0-8	C-X-C motif chemokine ligand 8	Homo sapiens	20-24	
23403077-8	2013	The growth of the tumor spheres could also be reduced by the CXCR2 specific inhibitor SB225002 or the PI3K/AKT inhibitor LY294002, indicating that the endogenously produced CXCL8 plays an autocrine role in the growth of the tumor spheres.	SB 225002	86-94	C-X-C motif chemokine ligand 8	Homo sapiens	173-178	
23611835-1	2013	SB225002 (SB) is an IL-8 receptor B (IL-8RB) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.	SB 225002	0-2	C-X-C motif chemokine ligand 8	Homo sapiens	20-24	
23611835-10	2013	In summary, the present study introduced SB as a promising antitumor agent which has the potential to exert its activity through dual mechanisms involving microtubules targeting and interference with IL-8-drivin cancer progression.	SB 225002	41-43	C-X-C motif chemokine ligand 8	Homo sapiens	200-204	
15028780-6	2004	Furthermore, the CXCR2-specific antagonist SB225002 [N-(2-hydroxy-4-nitrophenyl)-N"-(2-bromophenyl)urea] is 10-fold more potent in inhibiting IL-8 binding to hCXCR2 than to cCXCR2, suggesting that some of the observed differences in the amino acid sequences of the human and monkey receptor affect ligand binding sites or the conformation of the receptor.	SB 225002	43-51	C-X-C motif chemokine ligand 8	Homo sapiens	142-146	
15795529-4	2005	Competitive inhibition of the IL-8 receptor CXCR2 with the small molecule inhibitor SB225002 resulted in a 45-70% decrease in cervical explant susceptibility to HIV-1 infection.	SB 225002	84-92	C-X-C motif chemokine ligand 8	Homo sapiens	30-34	
15028780-6	2004	Furthermore, the CXCR2-specific antagonist SB225002 [N-(2-hydroxy-4-nitrophenyl)-N"-(2-bromophenyl)urea] is 10-fold more potent in inhibiting IL-8 binding to hCXCR2 than to cCXCR2, suggesting that some of the observed differences in the amino acid sequences of the human and monkey receptor affect ligand binding sites or the conformation of the receptor.	SB 225002	53-103	C-X-C motif chemokine ligand 8	Homo sapiens	142-146